Mycophenolate Mofetil Accord Healthcare

Mycophenolate Mofetil, the active ingredient in Mycophenolate Mofetil Accord Healthcare, is an immunosuppressant presented as an intravenous solution for intravenous use. It is employed to prevent acute organ rejection and to maintain long‑term immunosuppression in kidney, heart and liver transplant recipients.

GNH USA supplies Mycophenolate Mofetil Accord Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide, with distribution across EU and other global markets.

Mycophenolate Mofetil is used in organ transplantation to modulate the immune response and protect grafts.

- Kidney transplantation: prevents acute rejection and supports long‑term graft survival. - Heart transplantation: reduces incidence of acute rejection episodes. - Liver transplantation: maintains immunosuppression to protect graft function.

Adverse reactions may occur with Mycophenolate Mofetil therapy.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: frequent loose stools. - Vomiting: occasional emesis. - Abdominal pain: crampy discomfort. - Headache: transient head pain. - Tremor: mild shaking of hands.

Serious or Rare Side Effects: - Leukopenia: significant drop in white blood cells. - Infections: opportunistic or severe bacterial, viral, or fungal infections. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Malignancy: increased risk of certain cancers. - Severe anemia: marked reduction in red blood cells. - Pulmonary toxicity: rare lung inflammation.

Careful monitoring is required when using Mycophenolate Mofetil.

- Blood count monitoring: perform regular CBC to detect leukopenia or anemia. - Renal function: assess serum creatinine and eGFR periodically. - Hepatic function: check liver enzymes before and during therapy. - Pregnancy: avoid use in pregnancy due to teratogenic risk (Category D). - Live vaccines: contraindicated while on therapy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mycophenolate Mofetil may interact with several medicines.

Major Interactions (Avoid): - Azathioprine: additive bone‑marrow suppression. - Ribavirin: increased risk of hematologic toxicity. - Live vaccines: may cause severe infection. - Cholestyramine: reduces drug absorption. - Strong glucuronidation inhibitors: elevate mycophenolate levels.

Moderate Interactions (Monitor Closely): - Cyclosporine: raises mycophenolate exposure. - Tacrolimus: may increase nephrotoxicity. - ACE inhibitors: monitor renal function. - NSAIDs: watch for renal impairment. - Non‑live vaccines: assess immune response.